Chris Markoch

Chris Markoch

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

Clover Health Looks Primed to Go Out of This World

I feel almost certain that CLOV stock is going to move higher in the short term. How much higher and how long it will last are anybody’s guess.

Don’t Count on a Covid-19 Boost for Vaxart

VXRT stock remains a speculative bet as the company's chance to develop an oral Covid-19 vaccine grows slimmer every day.

Airbnb is a Disruptive Company That is Overvalued

After trading publicly for six months, ABNB stock is back to where it started. Investors may be realizing that the company uses tech, but is not a tech stock.

For ContextLogic, Growth Is More Than Just Wishful Thinking

If you’re patient and have an appetite for risk, then WISH stock has upside that shouldn’t be ignored. Here's why.

Cardano Has a Robust, Encouraging Roadmap for Future Development

Cardano gives investors tangible reasons to believe that ADA will be around for the long haul. And in an asset class where coins are sent “to the moon” on a lot less, those reasons may be enough to consider an investment.